Skip to main content

Table 1 The binding scores of individual peptides for the patient’s HLA class I and II haplotypes and CD1d

From: Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report

Peptide Protien origin Peptide sequence MHC class I Net MHC [32, 33] Syfpeithi [34] CD1d Castano [55] MHC class II Net MHC II pan3.1 [35]
1 RIM1 WEAKPSRIL B*18 WB +(17) CD1d − DRB1*1101 NB
    B*44 WB   CD1d − DRB1*1301 NB
   (WEAKPSRI) B*44 SB +(21) – −   
2 KIF4B GIAARVKNWL A*02 NB +(22) CD1d + DRB1*1101 WB
         DRB1*1301 WB
3 KIF4B KEGIAARVKNW B*44 WB −(14) CD1d + DRB1*1101 NB
         DRB1*1301 NB
   (EGIAARVKNW) B*44 SB −(14) CD1d +   
4 RIM1 EAKPSRILM A*02 NB −(6) CD1d − DRB1*1101 NB
         DRB1*1301 NB
  1. The binding scores of individual peptides for the patient’s HLA haplotypes were determined via NetMHC [32, 33], SYFPEITHI [34], CD1d-binding algorithm according to “Castano” (1-4-7 rule) [55] and NetMHCIIpan version 3.1 [35]
  2. Then likelihood for presentation is given as “+” and “−” respectively; SYFPEITHI half max scores regarding MHC class I presentation are given in brackets. Mutations in the peptides are indicated by underline
  3. WB weak binder, SB strong binder, NB no binding predicted
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us